Citius Oncology Soars 51.88% on Buy Rating, Price Target

On June 25, 2025, Citius Oncology's stock surged by 51.88% in pre-market trading, marking a significant rise in its stock performance.

Citius Oncology, Inc. is anticipated to achieve breakeven in the near future, making it an opportune time for analysis. The company's average price target is $6.00, which is 125.56% higher than the current price, with a consensus rating of "Buy".

On June 23, 2025, Citius Oncology experienced a notable decline of 16.35% in pre-market trading, reflecting the volatility in the biotech sector. This drop was followed by a significant rebound, indicating the stock's sensitivity to market fluctuations.

Analysts have given Citius Oncology a consensus rating of "Buy" with a price target of $6.00, suggesting a potential upside of 140.00%. This positive outlook from analysts has likely contributed to the recent surge in the stock price.